Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adlai Nortye Ltd. Sponsored ADR ( (ANL) ) has provided an announcement.
On February 3, 2026, Adlai Nortye Ltd. announced it had entered into securities purchase agreements for a private investment in public equity financing expected to raise approximately $140 million in gross proceeds through the sale of 64.6 million Class A ordinary shares (21.5 million ADS equivalents) at $2.1667 per share, with closing anticipated on February 4, 2026, subject to customary conditions. The deal, co-led by Cormorant Asset Management and Columbia Threadneedle Investments and supported by a syndicate of prominent healthcare investors, includes about $55 million of shares purchased by entities controlled by Chairman and CEO Yang Lu, underscoring insider confidence and bolstering the company’s capital base as it advances its RAS-targeting and next-generation immunotherapy pipeline; Jefferies, Leerink Partners, Lucid Capital Markets, H.C. Wainwright & Co. and Jones are serving as joint placement agents, and the company plans to register the resale of ADSs issued in the offering.
The most recent analyst rating on (ANL) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Adlai Nortye Ltd. Sponsored ADR stock, see the ANL Stock Forecast page.
More about Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. is a global clinical-stage biotechnology company focused on developing innovative cancer therapies, leveraging dual R&D operations in the United States and China. Its pipeline centers on next-generation cancer immunotherapies, including AN8025, a tri-functional fusion protein modulating T cells and antigen-presenting cells, and AN4005, an oral small-molecule PD-L1 inhibitor, as well as RAS-targeting therapies such as AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody-drug conjugate delivering a pan-RAS(ON) inhibitor directly to tumors.
Average Trading Volume: 756,088
Technical Sentiment Signal: Buy
Current Market Cap: $392.2M
Learn more about ANL stock on TipRanks’ Stock Analysis page.